NanoVibronix (NAOV) said Friday it completed its acquisition of privately-held ENvue Medical Holdings in a stock-for-stock transaction.
Under the deal, all of ENvue's outstanding equity interests were exchanged based on a fixed exchange ratio for consideration as a combination of about 1.7 million NanoVibronix common shares and 57,720 shares of series X non-voting convertible preferred stock, NanoVibronix said.
The company said that after the completion of the deal, a successor-in-interest of ENvue will be a wholly-owned unit of NanoVibronix.
The company also said concurrently with the deal's closing, it sold a $500,000 senior convertible debenture in a private placement.
NanoVibronix shares were up nearly 2% in recent trading.
Price: 0.48, Change: +0.01, Percent Change: +1.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.